People with diabetes can develop issues with the structure and function of their heart muscle known as diabetic cardiomyopathy. The ARISE-HF study is investigating if a new medicine, called AT-001, can prevent this condition from progressing to a more serious stage of heart failure. The study is recruiting people with type 2 diabetes who will either receive the new medicine or a dummy (placebo) treatment.

The ADAPT study is investigating a hybrid closed loop system of insulin control in people with type 1 diabetes. This system automatically monitors blood glucose and administers insulin without the participant needing to monitor, measure, or self-inject. This study is now closed to recruitment and is estimated to be complete in July 2022.

Dapagliflozin is a commonly used medicine in diabetes care, it helps control blood sugar and promotes weight-loss. The DETA trial is investigating if this medicine also improves physical health, the ability to undertake daily activities, and whether its effects can be further improved when paired with an exercise programme.

The inRange study is comparing two different long-acting insulin injections in patients with type 1 diabetes. The study will use continuous glucose monitoring to compare how long participants are in their goal glycaemic (blood sugar) range. This study is now complete and awaiting publication of results.

The Janssen UK trial team is very pleased to be able to share the most recent publicly available results from the ENSEMBLE (single dose) and ENSEMBLE-2 trials. If you took part in either of the trials, you can find important information about COVID-19 booster vaccines depending on whether you had two doses, one dose, or a placebo (dummy) vaccine below.

Trial results

The main findings from both trials are that a second dose (booster dose) of the Janssen COVID-19 vaccine gives:

• 94 percent protection when the booster is given at two months (results from USA)
• A four times increase in antibodies (immunity) when the booster given at two months
• A 12 times increase in antibodies (immunity) when the booster is given at six months

If you were part of the ENSEMBLE-2 trial and need advice about having a COVID-19 booster vaccine, from Janssen or as part of the NHS vaccination programme, please contact the study team on: Ensemble2_Mailbox@uhl-tr.nhs.uk

This phase 3 trial is looking at whether using the new drug tirzepatide helps to reduce the risk of heart disease for people with type 2 diabetes, compared to dulaglutide, which is an approved diabetes medication.